Obatoclax
An inhibitor of Bcl-2 family proteins.
General information
Obatoclax is an antiapoptic protein antagonist. It was suggested to be active against the early stages of SARS-CoV-2 infection via endosome pH neutralization (Varghese et al., 2021).
Obatoclax on DrugBank
Obatoclax on PubChem
Obatoclax on Wikipedia
CC1=CC(=C(N1)/C=C\2/C(=C/C(=C/3\C=C4C=CC=CC4=N3)/N2)OC)C
Supporting references
| Link | Tested on | Impact factor | Notes | Publication date |
|---|---|---|---|---|
|
Antiviral options against SARS-CoV-2 infection
Preprint Screening |
VERO E6 cell cultures | synergistic effect in combination with the virus-directed drug nelfinavir |
May/12/2020 | |
|
Berberine and Obatoclax Inhibit SARS-Cov-2 Replication in Primary Human Nasal Epithelial Cells In Vitro
Small molecule In vitro |
Vero E6 cells; human primary nasal epithelial cells; SARS-CoV-2 isolates BetaCoV/Munich/BavPat1/2020 and SARS-CoV-2/human/NLD/Nijmegen1/2020 | 3.82 | The compound inhibited SARS-CoV-2 in Vero E6 cells in a dose-dependent manner with an EC50 of 67 nM (or <40 nM for Nijmegen1 isolate) and a SI of >116. It was observed to act at the early stages of cell infection. In the nasal epithelial cell model, obatoclax was effective in inhibiting SARS-CoV-2 (BavPat1) infection with an EC50 of 0.2 μM and an SI of 32.7. |
Feb/11/2021 |
